| Bioactivity | DPP-4-IN-13 (compound 9i) is a competitive DPP4 inhibitor with the IC50 of 9.25 μM and can be used for study of type 2 diabetes[1]. |
| Formula | C25H24BrClN6O3 |
| Molar Mass | 571.85 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Baziar L, et al. Design, synthesis, biological evaluation and computational studies of 4-Aminopiperidine-3, 4-dihyroquinazoline-2-uracil derivatives as promising antidiabetic agents. Sci Rep. 2024;14(1):26538. |